Business Wire17d
QIAGEN takes legal action to defend QuantiFERON intellectual property and protect innovations in latent tuberculosis testing
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has filed a complaint against bioMérieux S.A. (EPA: BIM) for patent in ...
Zacks Investment Research on MSN8d
Is it Worth Retaining QIAGEN Stock in Your Portfolio Now?
QIAGEN N.V.’s QGEN fourth-quarter performance was driven by solid potential in molecular diagnostics. The company continues to progress with its test menu expansion, building a solid foundation to ...
EuropaWire13d
QIAGEN Gains FDA Approval for New QIAstat-Dx Gastrointestinal Panel 2 Mini B, Expanding Syndromic Testing Options
QIAGEN has received FDA approval for its QIAstat-Dx Gastrointestinal Panel 2 Mini B, expanding its syndromic testing offerings for gastrointestin ...
Nasdaq17d
QIAGEN Files Patent Complaint Against BioMérieux To Protect QuantiFERON Technology
(RTTNews) - QIAGEN N.V. (QGEN) announced that it has filed a complaint against bioMrieux S.A. for patent infringement, reinforcing its commitment to protecting the scientific advancements behind ...
Business Wire1mon
QIAGEN Strengthens Global Bioinformatics Leadership With New Data Center in Australia/Asia-Pacific Region
VENLO, The Netherlands & REDWOOD CITY, Calif.--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the official opening of a new data center in Melbourne ...